Akademik Veri Yönetim Sistemi
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, sa.5, ss.428-432, 2023 (ESCI)
Aim: The aim of this study was to evaluate pre-and post-treatment serum CTX levels of patients treated with bisphosphonate (BP) and the correlation of levels with MRONJ risk.Material and Methods: Patients treated with BP by the Endocrinology and Oncology Departments were included in this study. Blood samples were taken before and 12 months after BP treatment, and serum CTX values were determined with clinical examinations.Results: A total of 72 patients were included in the study. Of these patients, 32 had oncological and 40 had endocrinological disorders. The mean CTX value of all the patients was 453.7 (245.7-734.3) pg/ml, in oncology patients, it was 705.9 (398.6-945.6) pg/ml and in endocrine patients, it was 360.4 (209.2-598.2) pg/ml (p <0.001). The mean post-treatment CTX value of the remaining patients was 164.1 (106.9-301.8) pg/ml, and the difference was statistically significant before and after BP treatment (p <0.001). Among the patients included in the study, MRONJ was only observed in one oncology patient 18 months after the initial BP treatment.Discussion: MRONJ can be prevented by performing all dental treatments before BP treatment and eliminating local risk factors. CTX values should not only be evaluated after BP treatment, but also it may be useful to check before BP treatment to determine the course of the treatment.